Post-hoc Analysis of Descartes-08, BCMA-directed mRNA CAR-T Therapy, in Biologic Non-responsive Versus Biologic Naive Generalized Myasthenia Gravis: Results from a Phase 2b Randomized Trial (P9-9.020)

June 9, 2026Neurology

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to assess the effects of Descartes-08 therapy in patients with different responses to biologic therapies in generalized myasthenia gravis.
Phase 2b randomized trial comparing biologic non-responsive and naive patients.
Participants received BCMA-directed mRNA CAR-T therapy.
Post-hoc analysis conducted to evaluate treatment effects.
Specific treatment effects were observed, showing variations between biologic non-responsive and naive groups.
Statistical significance was noted in the response rates between the two patient categories.

Randomized trial compares effects of BCMA-directed mRNA CAR-T therapy in gMG, indicating treatment differences based on biologic response status.

To compare the effects of Descartes-08 in biologic non-responsive and biologic naive patients with generalized myasthenia gravis (gMG).

No takes yet. Share an insight, caveat, or question.

Miljkovic et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share